Humanwell Healthcare (600079.SH): Abiraterone acetate tablets obtained drug registration certificate.
Renfu Pharmaceutical (600079.SH) announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd....
Humanwell Healthcare (600079.SH) announced that its controlling subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Acetate Abiraterone Tablets. Acetate Abiraterone Tablets are used in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC), including those who have not received hormone therapy or have received hormone therapy for no more than 3 months.
Related Articles
Subsidiary of Qingdao Huicheng Environmental Technology Group(300779.SZ) successfully completes trial production of a demonstration project for comprehensive utilization of 200,000 tons of mixed waste plastics annually.
China Galaxy Securities: Accelerating Commercialization of AI, Optimistic about AI Computing Power Chain, Byte Ecology, and Vertical SAAS as the Three Main Themes.
CICC: It is expected that the global energy storage demand will remain high in 2025, focusing on opportunities for front-end and back-end energy storage.
Subsidiary of Qingdao Huicheng Environmental Technology Group(300779.SZ) successfully completes trial production of a demonstration project for comprehensive utilization of 200,000 tons of mixed waste plastics annually.
China Galaxy Securities: Accelerating Commercialization of AI, Optimistic about AI Computing Power Chain, Byte Ecology, and Vertical SAAS as the Three Main Themes.
CICC: It is expected that the global energy storage demand will remain high in 2025, focusing on opportunities for front-end and back-end energy storage.
